Diabetes Mellitus After Kidney Transplantation in the United States
By M. Schnitzler. American Journal of Transplantation, 2003
740 citations recorded by the source corpus.
I read with interest the report by Kasiske et al. concerning an analysis of new-onset diabetes mellitus, based on data from the United Renal Data System (1). The authors’ analysis of risk factors for new-onset diabetes and its clinical implications provides valuable evidence on this important issue, and highlights the need for management strategies that minimize risk of diabetes developing after transplantation. Their results concerning the incidence of new-onset diabetes and the increased relative risk of diabetes associated with tacrolimus-based immunosuppression are broadly in line with our own findings (2).
Subfields: Surgery, Transplantation
View Paper: https://www.semanticscholar.org/paper/c2dc70dae6ac39505eda757fb5936c0f7906500c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Surgery
In Transplantation
Citations in the corpus
- Rational Development of LEA29Y (belatacept), a High‐Affinity Variant of CTLA4‐Ig with Potent Immunosuppressive Properties (2005, background): “For example, the incidence of new onset immunosuppressive-related diabetes mellitus approaches 30% in the first 2 years following renal transplantation, conferring a significantly higher risk of death (23).”
- Results of an International, Randomized Trial Comparing Glucose Metabolism Disorders and Outcome with Cyclosporine Versus Tacrolimus (2007, background): “Meta- (14,15) and registry analyses (1,16) have indicated that tacrolimus is associated with increased incidence of NODAT.”
- Pathogenesis of Type 2 Diabetes Mellitus (2015, background): “Impair insulin-mediated suppression of hepatic glucose production [202].”